Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Working Capital to Net Assets Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Working Capital to Net Assets ratio of 73.9% as of March 2026. Working capital of CN¥1.69 Billion (current assets of CN¥1.79 Billion minus current liabilities of CN¥104.33 Million) is measured against net assets of CN¥2.28 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hubei Biocause Heilen Pharmaceutical Co. balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Working Capital to Net Assets (2017–2025)
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 73.9%, reflecting working capital of CN¥1.69 Billion against net assets of CN¥2.28 Billion CNY. Check Hubei Biocause Heilen Pharmaceutical Co. (301211) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 301211 market cap.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 73.8% | CN¥1.68 Billion | CN¥2.27 Billion | CN¥1.79 Billion | CN¥114.55 Million | ▼ -0.3 pp |
| 2024 | 74.0% | CN¥1.71 Billion | CN¥2.31 Billion | CN¥1.87 Billion | CN¥164.38 Million | ▼ -7.6 pp |
| 2023 | 81.6% | CN¥1.92 Billion | CN¥2.36 Billion | CN¥2.10 Billion | CN¥175.14 Million | ▼ -7.0 pp |
| 2022 | 88.6% | CN¥2.02 Billion | CN¥2.28 Billion | CN¥2.23 Billion | CN¥208.91 Million | ▼ -2.5 pp |
| 2021 | 91.2% | CN¥2.03 Billion | CN¥2.22 Billion | CN¥2.13 Billion | CN¥103.01 Million | ▲ +19.1 pp |
| 2020 | 72.0% | CN¥504.57 Million | CN¥700.39 Million | CN¥603.65 Million | CN¥99.09 Million | ▲ +6.0 pp |
| 2019 | 66.1% | CN¥322.50 Million | CN¥488.25 Million | CN¥575.44 Million | CN¥252.94 Million | ▼ -24.2 pp |
| 2018 | 90.2% | CN¥360.70 Million | CN¥399.87 Million | CN¥489.15 Million | CN¥128.46 Million | ▲ +33.1 pp |
| 2017 | 57.1% | CN¥175.67 Million | CN¥307.65 Million | CN¥350.77 Million | CN¥175.10 Million | — |